Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.61 |
| ▸ | BCHE | P06276 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27614960 | 0.85 | DNM1 (0.60) | DNM1BCHECHRM2MEN1KMT2A | |
| SCHEMBL2924382 | 0.84 | DNM1 (0.62) | DNM1BCHECHRM2MEN1KMT2A | |
| SCHEMBL27646012 | 0.81 | DNM1 (0.58) | DNM1BCHECHRM2MEN1KMT2A | |
| SCHEMBL26450919 | 0.81 | DNM1 (0.59) | DNM1BCHELMNAALDH1A1 | |
| SCHEMBL168266 | 0.81 | DNM1 (0.62) | DNM1BCHECHRM2MEN1KMT2A | |
| SCHEMBL6893475 | 0.80 | DNM1 (0.52) | DNM1BCHECHRM2MEN1KMT2A | |
| SCHEMBL7288681 | 0.80 | DNM1 (0.58) | DNM1BCHECHRM2MEN1KMT2A | |
| SCHEMBL13995736 | 0.80 | CHRM2 (0.59) | DNM1BCHECHRM2MEN1KMT2A | |
| SCHEMBL7288676 | 0.79 | DNM1 (0.57) | DNM1BCHECHRM2MEN1KMT2A | |
| SCHEMBL24494882 | 0.79 | ALDH1A1 (0.54) | DNM1BCHEMEN1KMT2AANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2022261243-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | DNM1 3558/4885BCHE 3739/4885CHRM2 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.